THIS PRESS RELEASE MAY NOT BE PUBLISHED, DISSEMINATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN

Advicenne announces the registration of its *Document De Base* in relation to its planned IPO on Euronext's regulated market in Paris

Advicenne is a specialist in the development of innovative pediatric-friendly treatments for orphan renal diseases

- Positive Phase III results for its lead product ADV7103 in distal renal tubular acidosis (dRTA)
- Orphan drug status for ADV7103 and commercialization in Europe anticipated around 2020 in the treatment of dRTA
- An original and innovative product development strategy backed by international clinical experts
- Proceeds from potential initial public offering (IPO) to pursue the clinical development of its lead product in Europe and the United States and preparing commercial launch in Europe

Nîmes, France, November 2, 2017 - Advicenne, a specialist pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today the filling of its *document de base* with the French financial market authority *(Autorité des Marchés Financiers* - the AMF) on October 31, 2017, under the number I.17-071. This registration marks the first stage of its planned IPO on Euronext's regulated market in Paris, which will be conducted subject to market conditions and the AMF's approval of the prospectus prepared in respect of the contemplated transaction.

Founded in 2007 by Dr. Luc-André Granier, MD, PhD and Caroline Roussel-Maupetit, Engineer, Advicenne is a pharmaceutical company focused on the development of products dedicated to rare renal and neurological diseases. The Company's strategy is to design innovative products targeting unmet medical needs which are adapted to all ages of life.

The Company intends to provide therapeutic solutions by specifically integrating pediatric considerations into the design and clinical development of its products. The treatments Advicenne develops are thus optimized to support the patient from early childhood throughout their lives.

Advicenne targets unmet medical needs through an original and 'de-risked'[1] development strategy

The Company develops its products in close collaboration with internationally recognized experts in their fields both in Europe and the United States. This strategy has allowed Advicenne to use its specific know-how to convert the needs expressed by these experts into products tailored to satisfy unmet needs by enhancing existing technologies. Using well known active pharmaceutical ingredients, the Company has the

[1] Taking into account the overall development of Advicenne's products which are, for most of them, in late-stage or in their final stages of clinical development and Advicenne's use of existing technologies.

necessary expertise to develop, register and market its product in a reduced time and save on the costs of certain early stages of development by using well-known active pharmaceutical ingredients.

This approach allowed Advicenne to conduct and finalize the clinical development of ADV6209, a pediatric formulation used for moderate sedation and pre-anesthesia medication, which was acquired by Primex Pharmaceuticals in 2016. The total amount of the transaction could reach approximately €40 million, subject to obtaining market authorization and for Primex Pharmaceuticals achieving certain sales objectives.

A portfolio of clinically advanced products

Advicenne has developed a portfolio of clinical products in nephrology and neurology. The Company's lead product ADV7103 is at an advanced clinical development stage in two indications in nephrology, dRTA and Cystinuria. ADV7103 has already shown positive phase III results in dRTA.

The other products in the portfolio target mainly orphan diseases and have the potential to drive growth in the medium and long-term or could be partnered.

ADV7103 / DISTAL TUBULAR ACIDOSIS (dRTA)

Advicenne's lead product has demonstrated efficacy in a pivotal Phase III study and has the potential to become the first approved treatment for dRTA

Advicenne's most advanced product, ADV7103, is being developed for the treatment of dRTA, an orphan nephrological disease. Based on the positive results of the European pivotal Phase III clinical study, which were presented in September 2017 at the European Congress of Nephro-pediatrics (ESPN), the Company believes that ADV7103 has the potential to become a reference drug for the treatment of this disease. At present, no drug is currently registered in Europe or the United States for dRTA.

ADV7103: Orphan drug status and expected commercialization in Europe and the United States around 2020/2021 respectively

In June 2017, the European Union granted the orphan drug designation for ADV7103 in the dRTA, allowing Advicenne to benefit from an exclusive marketing right in Europe for 10 years from the date of obtaining its marketing authorization. Advicenne aims to obtain a market authorization in 2019 and anticipates commercial launch in Europe around 2020.

The Company plans to initiate a pivotal Phase II/III clinical trial with ADV7103 in the United States for dRTA in 2018 with a commercial launch anticipated around 2021.

dRTA: an unmet medical need

dRTA is a disease that occurs when the kidneys do not properly remove acids from the blood into the urine. As a result, too much acid remains in the blood which generates an unbalanced blood pH causing complications such as stunting and rickets as well as a range of additional clinical disorders such as a potassium deficiency, which alters the function of several organs and more generally affecting the cardiovascular system. Moreover, a high concentration of calcium in the urine can cause kidney stones and calcinoses, which can lead to kidney dysfunction and eventually lead to renal failure.

The current treatments options for dRTA are heterogeneous and consist of non-approved products, which require to be administered every four to six hours in an attempt to rebalance the blood pH and normalize the

potassium level in the blood. ADV7103 offers the possibility of reducing the number of doses required by patients to only two doses per day.

Initially Advicenne intends to target its commercial activities towards patients suffering from the genetic form of the disease (which usually occurs during childhood) and in certain patients with well-known acquired forms of the disease as a result of autoimmune disease. The Company estimates that these patients represent a population of approximately 30,000 patients in Europe and 20,000 in the United States.

ADV7103 / CYSTINURIA

Advicenne is also developing ADV7103 in a second renal indication, cystinuria, a rare disease associated with the abnormal transport of amino acids in the renal tubule. A pivotal European Phase II/III clinical trial is expected to be initiated by the Company in 2018 to evaluate the efficacy and safety of ADV7103 in this indication.

Cystinuria is a hereditary disease affecting one in every 7,000 people and for which there is currently no registered first-line treatment in Europe. Characterized by the recurrent formation of kidney stones, cystinuria can develop at any age but clinical symptoms usually appear during the first 20 years of life.

A sales and marketing strategy based on a network of American and European opinion leaders

dRTA and cystinuria are pathologies treated by a very limited number of hospital specialists (mainly nephropediatricians, nephrologists and urologists), which will enable the Company to optimize its investments in commercializing its products.

The Company plans to develop its business by its own means, particularly in the five major European countries including France, Germany, the United Kingdom, Italy and Spain. The Company intends to negotiate distribution contracts in other major European countries. For the United States, Advicenne aims to find a commercial partner following the clinical trials and registration process to maximize the value for its shareholders.

Dr. Luc-André Granier, CEO and co-founder of Advicenne, says, "*Advicenne was created to provide innovative and improved treatments for patients suffering from orphan renal and neurological diseases for which there are currently no effective treatments. Our original strategy of meeting the therapeutic needs expressed by opinion leaders, combined with our development expertise, has largely been validated by the positive results of the Phase III clinical trial of our flagship product ADV7103. These positive results will enable us to submit the application file for marketing authorization in 2018 in Europe for dRTA. We look forward to continuing to advance the clinical development of ADV7103 by opening two pivotal Phase II/III trials in the United States for dRTA and later in Europe for cystinuria. We believe that this strategy will continue to deliver value as we progress the final stages of the development of ADV7103. ADV7103 is expected to be launched for its first indication in Europe around 2020.*"

Advicenne has received support from leading investors

Since its inception, the Company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.

Document de base availability

Copies of the document de base filed with the AMF on October 31, 2017 under number I.17-071 are available upon request and free of charge at the registered office of Advicenne, 2 Rue Briçonnet, 30,000 Nîmes. The document de base can be consulted on the AMF's website (www.amf-france.org) and the company's website (www.advicenne.com).

Risk factors

The public's attention is drawn to chapter 4 "Risk factors" of the document de base filed with the AMF and in particular the risks associated with historic or futures losses and the Company's product portfolio which the Company might not be able to expand.

For more information about Advicenne's intention to float, please visit:
http://advicenne-ipo.com

About Advicenne

Advicenne is a late-stage pharmaceutical company focusing on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company's most advanced product is ADV7103 which has shown positive results in a pivotal phase III study in children and adults with distal Renal Tubular Acidosis (dRTA). ADV7103 is also being developed in a second indication for the treatment of Cystinuria, an inherited renal tubulopathy and is expected to enter into a pivotal Phase III clinical trial in 2018 in Europe.

In addition to ADV7103, the Company has a portfolio of clinical and pre-clinical products targeting critical unmet needs in nephrology and neurology in collaboration with Key Opinion Leaders.

The Company was established in 2007 in Nimes (France). Since its inception, the Company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.

Additional information about Advicenne is available through its website: www.advicenne.com

Contacts:

Advicenne

LA Granier, S Delbaere, J Rachline
investors@advicenne.com
+33 (0)4 66 05 54 20

Media relations

Citigate Dewe Rogerson
David Dible, Sylvie Berrebi, Marine Perrier (Londres)
Laurence Bault, Alexandre Dechaux (Paris)
advicenne@citigatedewerogerson.co.uk
+44 (0) 20 7638 9571 / +33 (0)1 53 32 78 87

Legal Disclaimer:

This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States of America, Canada, Australia or Japan.

The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.

This press release is an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003, as amended (the "Prospectus Directive").

With respect to the member States of the European Economic Area which have implemented the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State other than France. As a result, the securities may not and will not be offered in any relevant member State other than France except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member State, or under any other circumstances which do not require the publication by Advicenne of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member State.

It does not constitute an offer to purchase or to subscribe for securities in the United States or in any other jurisdiction.

The securities referred to herein may not be offered or sold in the United States of America absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended. Advicenne does not intend to register all or any portion of the offering of the securities in the United States of America or to conduct a public offering of the securities in the United States of America.

This communication does not constitute an offer of the securities to the public in the United Kingdom. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.